A bispecific antibody against a broad spectrum of novel coronaviruses
By developing bispecific antibodies targeting the novel coronavirus, using multiple non-overlapping binding sites, the problem of drug resistance of existing antibodies to Omickron mutant strains has been solved, and a variety of new coronavirus epidemic strains have been achieved efficient neutralization and broad spectrum protection.
Patent Information
- Application Number
- CN202311506313.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2023-02-24
- Filing Date
- 2023-11-13
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2043-11-13
AI Technical Summary
Existing neutralizing antibodies show resistance to the Omickron variant strain and its submutant strain of the novel coronavirus, making it difficult to effectively resist viral mutations, especially the single binding site of monoclonal antibody, which brings mutations. risk.
Develop a bispecific antibody of a broad-spectrum novel coronavirus that utilizes multiple targeting multiple epitopes by targeting different epitopes of the SARS-CoV-2 RBD domain, including the first targeting domain D1 and the second targeting domain D2. Non-overlapping binding sites enhance affinity and neutralization activity for the virus.
It has achieved efficient neutralization of a variety of new crown epidemic strains, which is significantly better than the combination of the existing antibody LY-CoV1404 and monoclonal antibody, with broad-spectrum ability and high affinity, reducing the risk brought by viral mutations.
Smart Images

Figure BDA0004545986750000181 
Figure BDA0004545986750000221 
Figure BDA0004545986750000222
Abstract
Description
Technical Field
[0001] The present invention relates to the field of fusion protein technology, and more specifically, to a bispecific antibody for a broad spectrum of novel coronaviruses. Background Art
[0002] According to the latest data from the World Health Organization (WHO), the new coronavirus (SARS-CoV-2) seriously endangers human physical and mental health and life safety. People of all ages are at risk of infection with SARS-CoV-2 and its serious illness; people aged ≥60 years, those living in nursing homes or long-term care facilities, and those with chronic diseases are more likely to develop severe COVID-19 disease. Currently, the Omicron variant has become the main strain worldwide. It has stronger transmission ability, faster transmission speed, lower infection dose, stronger immune escape ability, and is constantly mutating to form new sub-variants. It has shown significant resistance to some previously approved vaccines and monoclonal antibodies for prevention and treatment. Among the neutralizing antibodies currently available in the world, only Eli Lilly's LY-CoV1404 still has a protective effect against BA.5, but it is no longer effective against the dominant BQ.1.1 and XBB.
[0003] According to the mutation trend of the new coronavirus, protective antibodies that can resist new mutant viruses are urgently needed. In particular, it is necessary to find antibodies that can target the conserved regions of the virus (that is, regions that are not easy to mutate) so that the antibodies have a strong ability to resist the risk of viral evolution (mutation). Due to the single binding site of the monoclonal antibody, the ability to resist viral mutation again is highly uncertain, which brings greater risks. Bispecific antibodies can have more non-overlapping binding sites and can target different regions of the virus. Even if the virus has one or two more mutation sites, it will not affect the affinity and neutralizing activity of the bispecific antibody for the virus, thereby further reducing the risk of viral mutation again.
[0004] Therefore, there is an urgent need in the art to develop a broad-spectrum bispecific antibody for the new coronavirus. Summary of the invention
[0005] The purpose of the present invention is to provide a bispecific antibody for a broad spectrum of novel coronaviruses.
[0006] In a first aspect of the present invention, a bispecific antibody against the new coronavirus is provided, wherein the bispecific antibody comprises:
[0007] A first targeting domain D1, which targets a first epitope of the SARS-CoV-2 RBD domain; and
[0008] A second targeting domain D2, which targets a second epitope of the SARS-CoV-2 RBD domain;
[0009] Wherein, the first epitope of the SARS-CoV-2 RBD domain has one or more of the following sites selected from the RBD region of the S protein: 346R, 437N, 438S, 439N, 440N, 441L, 443S, 444K, 445V, 446G, 447G, 448N, 449Y, 450N, 498Q, 499P, 500T, 506Q;
[0010] The second epitope of the SARS-CoV-2 RBD domain has one or more of the following sites selected from the RBD region of the S protein: 352A, 353W, 355R, 357R, 393T, 394N, 396Y, 462K, 463P, 464F, 465E, 466R, 468I, 516E, 518L, 519H, and 520A.
[0011] In another preferred example, the first epitope has 1-n selected from the following sites in the RBD region of the S protein: 346R, 437N, 438S, 439N, 440N, 441L, 443S, 444K, 445V, 446G, 447G, 448N, 449Y, 450N, 498Q, 499P, 500T, 506Q, wherein n is selected from 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18.
[0012] In another preferred example, the second epitope has 1-m selected from the following sites in the RBD region of the S protein: 352A, 353W, 355R, 357R, 393T, 394N, 396Y, 462K, 463P, 464F, 465E, 466R, 468I, 516E, 518L, 519H, 520A, wherein m is selected from 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or 17.
[0013] In another preferred example, the first epitope and the second epitope do not overlap or substantially do not overlap.
[0014] In another preferred embodiment, the D1 or D2 is independently selected from: Fab, Fab', F(ab')2, Fv fragment, single-chain Fv (scFv) fragment and single-domain fragment, preferably single-chain Fv (scFv), Fv fragment or Fab fragment.
[0015] In another preferred example, D1 and D2 are connected in series or in parallel, preferably in series.
[0016] In another preferred example, the bispecific antibody further comprises an optional third targeting binding domain D3.
[0017] In another preferred embodiment, the third targeting binding domain targets the third epitope of the SARS-CoV-2 RBD domain.
[0018] In another preferred embodiment, the third targeting binding domain is selected from: Fab, Fab', F(ab')2, Fv fragment, single-chain Fv (scFv) fragment and single domain fragment, preferably single-chain Fv (scFv), Fv fragment or Fab fragment.
[0019] In another preferred embodiment, the first targeting domain D1 comprises a first heavy chain variable region and a first light chain variable region, wherein:
[0020] The first heavy chain variable region comprises: HCDR1, HCDR2 and HCDR3 whose amino acid sequences are shown in SEQ ID NO: 11, SEQ ID NO: 12 and SEQ ID NO: 13, respectively;
[0021] The first light chain variable region comprises: LCDR1, LCDR2 and LCDR3, whose amino acid sequences are shown in SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 16, respectively.
[0022] In another preferred embodiment, the first heavy chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 23, or an amino acid sequence having at least 95%, 96%, 97%, 98% or 99% sequence identity with the amino acid sequence as shown in SEQ ID NO: 23 (wherein the CDR region is unchanged or substantially unchanged), or consists of the same; and / or
[0023] The first light chain variable region comprises, or consists of, an amino acid sequence as shown in SEQ ID NO:24, or an amino acid sequence having at least 95%, 96%, 97%, 98% or 99% sequence identity with the amino acid sequence as shown in SEQ ID NO:24 (wherein the CDR region is unchanged or substantially unchanged).
[0024] In another preferred example, the amino acid sequence of the first heavy chain variable region is shown as SEQ ID NO:23; and the amino acid sequence of the first light chain variable region is shown as SEQ ID NO:24.
[0025] In another preferred embodiment, the second targeting domain D2 comprises a second heavy chain variable region and a second light chain variable region, wherein:
[0026] The second heavy chain variable region comprises: HCDR1, HCDR2 and HCDR3 whose amino acid sequences are shown in SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO: 19, respectively;
[0027] The second light chain variable region comprises: LCDR1, LCDR2 and LCDR3, whose amino acid sequences are shown as SEQ ID NO: 20, SEQ ID NO: 21 and SEQ ID NO: 22, respectively.
[0028] In another preferred embodiment, the second heavy chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 25, or an amino acid sequence having at least 95%, 96%, 97%, 98% or 99% sequence identity with the amino acid sequence as shown in SEQ ID NO: 25 (wherein the CDR region is unchanged or substantially unchanged), or consists of the same; and / or
[0029] The second light chain variable region comprises, or consists of, an amino acid sequence as shown in SEQ ID NO:26, or an amino acid sequence having at least 95%, 96%, 97%, 98% or 99% sequence identity with the amino acid sequence as shown in SEQ ID NO:26 (wherein the CDR region is unchanged or substantially unchanged).
[0030] In another preferred example, the amino acid sequence of the second heavy chain variable region is shown as SEQ ID NO:25; and the amino acid sequence of the second light chain variable region is shown as SEQ ID NO:26.
[0031] In another preferred embodiment, the bispecific antibody is a homodimer or a heterodimer.
[0032] In another preferred embodiment, the bispecific antibody is formed by fusion of the antigen-binding fragments of D1 and D2, and has two pairs of symmetrical peptide chains, each pair of peptide chains is connected by a disulfide bond, and any pair of peptide chains has a structure as shown in formula ad from the N-terminus to the C-terminus:
[0033] VH1-L1-VL2-L2-VH2-L3-VL1-L4-Fc type a
[0034] VL1-L1-VH2-L2-VL2-L3-VH1-L4-Fc type b
[0035] VH2-L1-VL1-L2-VH1-L3-VL2-L4-Fc type c
[0036] VL2-L1-VH1-L2-VL1-L3-VH2-L4-Fc formula d;
[0037] in,
[0038] VH1 is the first heavy chain variable region, VL1 is the first light chain variable region;
[0039] VH2 is the second heavy chain variable region, VL2 is the second light chain variable region;
[0040] L1, L2, L3, and L4 are each independently none, a bond, or a linker;
[0041] Fc is the Fc element;
[0042] “-” represents a peptide bond.
[0043] In another preferred embodiment, the Fc element includes Fc wild type or Fc mutant type.
[0044] In another preferred embodiment, the Fc element is derived from IgG1 or IgG4.
[0045] In another preferred embodiment, the Fc mutant is derived from the Fc fragment of IgG1.
[0046] In another preferred embodiment, the Fc mutant has L234A and L235A mutations; and / or M252Y, S254T and T256E mutations.
[0047] In another preferred embodiment, the joint is a rigid joint or a flexible joint.
[0048] In another preferred embodiment, L1, L2, L3, and L4 are each independently none or (GS)1, (G4S)1 (l is selected from 1-6).
[0049] In another preferred embodiment, the VH1 comprises: HCDR1, HCDR2 and HCDR3 whose amino acid sequences are shown in SEQ ID NO: 11, SEQ ID NO: 12 and SEQ ID NO: 13 respectively;
[0050] The VL1 comprises: LCDR1, LCDR2 and LCDR3, whose amino acid sequences are shown in SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 16 respectively.
[0051] In another preferred embodiment, the VH2 comprises: HCDR1, HCDR2 and HCDR3 whose amino acid sequences are shown in SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO: 19 respectively;
[0052] The VL2 comprises: LCDR1, LCDR2 and LCDR3, whose amino acid sequences are shown in SEQ ID NO: 20, SEQ ID NO: 21 and SEQ ID NO: 22, respectively.
[0053] In another preferred example, the bispecific antibody has an amino acid sequence selected from any one of SEQ ID NOs. 1-4 and 27.
[0054] In another preferred embodiment, the bispecific antibody further comprises an active fragment and / or derivative of the bispecific antibody, and the derivative of the antibody has at least 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity with the bispecific antibody of the present invention.
[0055] In the second aspect of the present invention, a polynucleotide is provided, wherein the polynucleotide encodes the bispecific antibody according to the first aspect of the present invention.
[0056] In the third aspect of the present invention, a vector is provided, wherein the vector contains the polynucleotide described in the second aspect of the present invention.
[0057] In another preferred embodiment, the vector includes plasmid, bacteriophage, yeast plasmid, plant cell virus, mammalian cell virus such as adenovirus, retrovirus, or other vectors.
[0058] In the fourth aspect of the present invention, a host cell is provided, wherein the host cell contains the vector described in the third aspect of the present invention or the polynucleotide described in the second aspect of the present invention is integrated into its genome.
[0059] In another preferred embodiment, the host cell is a eukaryotic cell, preferably a mammalian cell.
[0060] In a fifth aspect of the present invention, a method for preparing the bispecific antibody according to the first aspect of the present invention is provided, comprising the steps of:
[0061] (i) culturing the host cell according to the fourth aspect of the present invention under appropriate conditions to obtain a mixture containing the bispecific antibody according to the first aspect of the present invention;
[0062] (ii) purifying and / or separating the mixture obtained in step (i) to obtain the bispecific antibody according to the first aspect of the present invention.
[0063] In a sixth aspect of the present invention, a pharmaceutical composition is provided, comprising:
[0064] (I) the bispecific antibody according to the first aspect of the present invention; and
[0065] (II) a pharmaceutically acceptable carrier.
[0066] In another preferred embodiment, the pharmaceutical composition further comprises other pharmaceutically active agents.
[0067] In another preferred embodiment, the other pharmaceutically active agents include other antiviral agents, such as favipiravir, remdesivir or interferon.
[0068] In another preferred embodiment, the pharmaceutical composition is in the form of a nasal spray, an oral preparation, a suppository or a parenteral preparation.
[0069] In another preferred embodiment, the nasal spray is selected from aerosols, sprays and powder sprays.
[0070] In another preferred embodiment, the oral preparation is selected from tablets, powders, pills, powders, granules, fine granules, soft / hard capsules, film-coated capsules, pellets, sublingual tablets and ointments.
[0071] In another preferred embodiment, the parenteral preparation is a transdermal preparation, an ointment, a plaster, an external liquid, an injectable or pushable preparation.
[0072] In a seventh aspect of the present invention, an immunoconjugate is provided, comprising:
[0073] (a) the bispecific antibody according to the first aspect of the present invention; and
[0074] (b) a conjugated moiety selected from the group consisting of a detectable label, a drug, a toxin, a cytokine, a radionuclide, an enzyme, or a combination thereof.
[0075] In another preferred embodiment, the conjugate portion is selected from: fluorescent or luminescent markers, radioactive markers, MRI (magnetic resonance imaging) or CT (computer tomography) contrast agents, or enzymes capable of producing detectable products, radionuclides, biotoxins, cytokines (such as IL-2, etc.), antibodies, antibody Fc fragments, antibody scFv fragments, gold nanoparticles / nanorods, viral particles, liposomes, and nanomagnetic particles.
[0076] In the eighth aspect of the present invention, there is provided a use of the bispecific antibody as described in the first aspect of the present invention, the pharmaceutical composition as described in the sixth aspect of the present invention, or the immunoconjugate as described in the seventh aspect of the present invention for preparing (a) a detection reagent or a kit; and / or (b) a drug for preventing and / or treating novel coronavirus infection.
[0077] In the ninth aspect of the present invention, a kit is provided, comprising the bispecific antibody as described in the first aspect of the present invention, the polynucleotide as described in the second aspect of the present invention, the vector as described in the third aspect of the present invention, the host cell as described in the fourth aspect of the present invention, the pharmaceutical composition as described in the sixth aspect of the present invention, or the immunoconjugate as described in the seventh aspect of the present invention.
[0078] In the tenth aspect of the present invention, there is provided a use of the bispecific antibody as described in the first aspect of the present invention, the polynucleotide as described in the second aspect of the present invention, the vector as described in the third aspect of the present invention, the host cell as described in the fourth aspect of the present invention, the pharmaceutical composition as described in the sixth aspect of the present invention, or the immunoconjugate as described in the seventh aspect of the present invention in the preparation of a medicament for preventing, treating and / or detecting infection with a novel coronavirus; preferably, the novel coronavirus is a prototype strain of SARS-CoV-2 and / or a variant strain of SARS-CoV-2.
[0079] In another preferred embodiment, the SARS-CoV-2 variant strain is selected from: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Kappa (B.1.617.1), Delta (B.1.617.2) variants of SARS-CoV-2 and Omicron (B.1.1.529) and its sub-variants.
[0080] In another preferred embodiment, the new coronavirus is SARS-CoV-2 selected from the following group: prototype strain, BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.3, BA.4, BA.5, BF.7, BQ.1, BQ.1.1, XBB, XBB.1.5, XBB.1.16, and EG.5 mutant strains.
[0081] In the eleventh aspect of the present invention, a method for preventing, treating and / or detecting novel coronavirus infection is provided, wherein a safe and effective amount of the bispecific antibody as described in the first aspect of the present invention, the pharmaceutical composition as described in the sixth aspect of the present invention, or the immunoconjugate as described in the seventh aspect of the present invention is administered to a subject in need.
[0082] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS
[0083] Figure 1A A schematic diagram of the bispecific antibody structure is shown in which the light and heavy chain variable regions of CoV56 monoclonal antibody (abbreviated as 56) and L4.65 monoclonal antibody (abbreviated as 65) are arranged in different orders.
[0084] Figure 1B The bispecific antibody protein structure of the present invention is shown.
[0085] Figure 1CThe binding epitopes of 65 monoclonal antibodies and the RBD region of the 2019-nCovS protein (a) and the binding epitopes of 56 monoclonal antibodies and the RBD region of the 2019-nCovS protein (b) are shown.
[0086] Figure 2A The enzyme-linked immunosorbent assay was used to determine the binding ability of the new coronavirus antibodies to 2019-nCov.
[0087] Figure 2B The enzyme-linked immunosorbent assay was used to determine the binding ability of the new coronavirus antibodies to BA.1.1.
[0088] Figure 2C The enzyme-linked immunosorbent assay was used to determine the binding ability of the new coronavirus antibodies to BA.2.12.1.
[0089] Figure 2D The enzyme-linked immunosorbent assay was used to determine the binding ability of the new coronavirus antibody to BA.5.
[0090] Figure 2E The enzyme-linked immunosorbent assay was used to determine the binding ability of the new coronavirus antibody to BF.7.
[0091] Figure 2F The enzyme-linked immunosorbent assay was used to determine the binding ability of the new coronavirus antibodies to BQ.1.1.
[0092] Figure 2G The enzyme-linked immunosorbent assay was used to determine the binding ability of the new coronavirus antibodies to XBB.
[0093] Figure 3 The pseudovirus neutralizing activity of DIA-19 against different mutant strains of the new coronavirus is shown, among which L4.65 represents monoclonal antibody 65, Cov56 represents monoclonal antibody 56, Cocktail represents the combination of monoclonal antibodies 65 and 56, and the wild type (prototype) represents 2019-nCov.
[0094] Figure 4A The results show that the new coronavirus antibodies have the ability to neutralize the live 2019-nCov (PT) virus.
[0095] Figure 4B It shows the neutralizing ability of the new coronavirus antibodies against the Delta live virus.
[0096] Figure 4C It shows the neutralizing ability of the new coronavirus antibodies against the live BA.5.2 virus.
[0097] Figure 4D The results show that the new coronavirus antibodies have the ability to neutralize the BF.7 live virus.
[0098] Figure 4E It shows the neutralizing ability of the new coronavirus antibodies against the live BQ.1 virus.
[0099] Figure 4F It shows the neutralizing ability of the new coronavirus antibodies against the BQ.1.1 live virus.
[0100] Figure 4G It shows the neutralizing ability of the new coronavirus antibodies against the live XBB virus.
[0101] Figure 5 The neutralization synergistic effect of DIA-19 on SARS-CoV-2EG.5 mutant pseudovirus was shown.
[0102] Fig. 6A Shows the changes in mouse body weight after infection with SARS-CoV-2XBB strain in the DIA-19 prevention experiment.
[0103] Figure 6B The viral load in the lungs and nasal cavity of mice after infection with the SARS-CoV-2XBB strain in the DIA-19 prevention experiment is shown, ns:p>0.05; *:p<0.05; **:p<0.01; ***:p<0.001; ****:p<0.0001.
[0104] Fig. 7A Shows the changes in mouse body weight after infection with SARS-CoV-2XBB strain in the DIA-19 intraperitoneal injection treatment experiment.
[0105] Figure 7B The results show the viral load in the lungs and nasal cavity of mice after infection with the SARS-CoV-2XBB strain in the DIA-19 intraperitoneal injection treatment experiment, ns: p>0.05; *: p<0.05; **: p<0.01; ***: p<0.001; ****: p<0.0001.
[0106] Figure 8 The figure shows the number of viral copies (Log10 copies / g) in the lung and brain tissues of mice on the 3rd day (3dpi) after infection with SARS-CoV-2Delta strain in the prevention experiment, ns:p>0.05; *:p<0.05; **:p<0.01; ***:p<0.001; ****:p<0.0001.
[0107] Fig. 9 The number of viral copies (Log10 copies / g) in the lung and brain tissues of mice on the 3rd day after infection with the SARS-CoV-2Delta strain (3dpi) in the treatment experiment is shown, ns: p>0.05; *: p<0.05; **: p<0.01; ***: p<0.001; ****: p<0.0001. DETAILED DESCRIPTION
[0108] After extensive and in-depth research and a large number of screenings, the inventors unexpectedly constructed for the first time a highly specific, high-affinity and high-broad-spectrum bispecific antibody targeting different epitopes in the RBD region of the new coronavirus. Specifically, the ultra-broad-spectrum fully human monoclonal antibodies CoV56 and L4.65, which are based on the isolation of two non-competitive monoclonal antibodies from the bodies of those immunized with the new crown recombinant protein vaccine disclosed in Chinese patent applications 202211588062.X and 202211538937.5, were designed to be a new type of bispecific antibody through a unique fusion. Compared with the parent monoclonal antibody, it has higher inhibitory activity and broad-spectrum ability for all Omicron strains detected (including the most popular BA.5.2, BF.7, and XBB subspecies in China). The present invention was completed on this basis.
[0109] the term
[0110] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0111] The term "about" can refer to a value or composition that is within an acceptable error range for the particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined.
[0112] As used herein, the term "comprising" or "including (comprising)" may be open, semi-closed and closed. In other words, the term also includes "consisting essentially of" or "consisting of".
[0113] Generally, "antibodies" are also referred to as "immunoglobulins" which may be natural or conventional antibodies in which two heavy chains are linked to each other by disulfide bonds and each heavy chain is linked to a light chain by a disulfide bond. There are two types of light chains, λ (l) and κ (k). There are five major heavy chain species (or isotypes) that determine the functional activity of the antibody molecule: IgM, IgD, IgG, IgA, and IgE. Each chain contains different sequence domains. The light chain includes two domains or regions, a variable domain (VL) and a constant domain (CL). The heavy chain includes four domains, a heavy chain variable region (VH) and three constant regions (CH1, CH2, and CH3, collectively referred to as CH). The variable regions of both the light chain (VL) and the heavy chain (VH) determine the binding recognition and specificity to the antigen. The constant domain (CL) of the light chain and the constant region (CH) of the heavy chain confer important biological properties such as antibody chain binding, secretion, transplacental mobility, complement binding, and binding to Fc receptors (FcR). The Fv fragment is the N-terminal portion of the immunoglobulin Fab fragment and is composed of the variable portion of a light chain and a heavy chain. The specificity of the antibody depends on the structural complementarity between the antibody binding site and the antigenic determining region. The antibody binding site is composed of residues mainly from the hypervariable region or complementary determining region (CDR). Occasionally, residues from non-hypervariable or framework regions (FR) affect the overall domain structure and thus the binding site. The complementary determining region or CDR refers to the amino acid sequence that jointly defines the binding affinity and specificity of the natural Fv region of the natural immunoglobulin binding site. The light chain and heavy chain of the immunoglobulin each have three CDRs, which are separately referred to as CDR1-L, CDR2-L, CDR3-L and CDR1-H, CDR2-H, CDR3-H. Conventional antibody antigen binding sites therefore include six CDRs, including a set of CDRs from each heavy chain and light chain v region.
[0114] In a given antibody light chain variable region or heavy chain variable region amino acid sequence, the precise amino acid sequence boundaries of each CDR can be determined using any one or a combination of a number of well-known antibody CDR assignment systems, including, for example: Chothia based on the three-dimensional structure of the antibody and the topology of the CDR loops, Kabat based on antibody sequence variability (Kabat, E., et al., US Department of Health and Human Services, Sequences of Proteins of Immunological Interest, (1983), AbM (University of Bath), Contact (University College London), the International ImmunoGene Tics database (IMGT), the EU numbering system, and the Chothia definition based on loop structural position.
[0115] It should be understood that the precise amino acid sequence boundaries of the CDRs in the present invention may optionally be defined using the different assignment systems mentioned above. Preferably, unless otherwise indicated, in the present invention, when referring to residue positions in the antibody variable region (including heavy chain variable region residues and light chain variable region residues), it refers to the numbering positions according to the Kabat numbering system.
[0116] As used herein, the term "variable" means that some parts of the variable region in an antibody are different in sequence, which forms the binding and specificity of various specific antibodies to their specific antigens. However, variability is not evenly distributed throughout the variable region of an antibody. It is concentrated in three fragments called complementary determining regions (CDRs) or hypervariable regions in the variable regions of light and heavy chains. The more conservative part of the variable region is called the framework region (FR). The variable regions of natural heavy and light chains each contain four FR regions, which are roughly in a β-folded configuration, connected by three CDRs forming a connecting loop, and in some cases can form a partial β-folded structure. The CDRs in each chain are closely together through the FR region and together with the CDRs of another chain form the antigen-binding site of the antibody (see Kabat et al., NIH Publ. No. 91-3242, Volume I, 647-669 pages (1991)). The constant region does not directly participate in the binding of the antibody to the antigen, but they exhibit different effector functions, such as participating in the antibody's antibody-dependent cytotoxicity.
[0117] As used herein, the term "framework region" (FR) refers to the amino acid sequence inserted between CDRs, i.e., refers to those parts of the light chain and heavy chain variable regions of immunoglobulins that are relatively conserved between different immunoglobulins in a single species. The light chain and heavy chain of an immunoglobulin each have four FRs, referred to as FR1-L, FR2-L, FR3-L, FR4-L and FR1-H, FR2-H, FR3-H, FR4-H, respectively. Accordingly, the light chain variable domain can therefore be referred to as (FR1-L)-(CDR1-L)-(FR2-L)-(CDR2-L)-(FR3-L)-(CDR3-L)-(FR4-L) and the heavy chain variable domain can therefore be represented as (FR1-H)-(CDR1-H)-(FR2-H)-(CDR2-H)-(FR3-H)-(CDR3-H)-(FR4-H). Preferably, the FR of the present invention is a human antibody FR or a derivative thereof, wherein the derivative of the human antibody FR is substantially identical to the naturally occurring human antibody FR, i.e., the sequence identity reaches 85%, 90%, 95%, 96%, 97%, 98% or 99%.
[0118] Knowing the amino acid sequence of the CDRs, one skilled in the art can easily determine the framework regions FR1-L, FR2-L, FR3-L, FR4-L and / or FR1-H, FR2-H, FR3-H, FR4-H.
[0119] As used herein, the term "human framework region" is a framework region that is substantially identical (about 85% or more, specifically 90%, 95%, 97%, 99% or 100%) to the framework region of a naturally occurring human antibody.
[0120] As used herein, the term "monoclonal antibody" or "mAb" refers to an antibody molecule with a single amino acid composition directed against a specific antigen, and should not be construed as requiring the antibody to be produced by any particular method. Monoclonal antibodies can be produced by a single clone of a B cell or hybridoma, but can also be recombinant, i.e., produced by protein engineering.
[0121] As used herein, the term "antigen" or "target antigen" refers to a molecule or portion of a molecule that can be bound by an antibody or antibody-like binding protein. The term further refers to a molecule or portion of a molecule that can be used in an animal to produce an antibody that can bind to an epitope of the antigen. A target antigen may have one or more epitopes. For each target antigen recognized by an antibody or by an antibody-like binding protein, the antibody-like binding protein can compete with an intact antibody that recognizes the target antigen.
[0122] As used herein, the term "affinity" is theoretically defined by the equilibrium association between a complete antibody and an antigen. The affinity of the bispecific antibodies of the present invention can be evaluated or determined by KD values (dissociation constants) (or other determination methods), such as bio-layer interferometry (Bio-layer interferometry BLI), using a FortebioRed96 instrument to measure and determine.
[0123] As used herein, the term "linker" refers to one or more amino acid residues inserted into an immunoglobulin domain that provide sufficient mobility for the light and heavy chain domains to fold into an exchange dual variable region immunoglobulin.
[0124] Suitable examples of linkers include single glycine (Gly) or serine (Ser) residues, and the identity and sequence of amino acid residues in the linker can vary with the type of secondary structural elements to be achieved in the linker. Preferred linkers can be (GS)1, (G4S)1 (1 is selected from 1-6).
[0125] "ECMO" refers to Extracorporeal Membrane Oxygenation (ECMO), which is a medical emergency technology equipment that is mainly used to provide continuous extracorporeal respiration and circulation to patients with severe cardiopulmonary failure to maintain the patient's life.
[0126] "ICU" refers to the Intensive Care Unit, where treatment, nursing and rehabilitation can be carried out simultaneously. It provides space and equipment for critically ill or comatose patients, and offers the best care, comprehensive treatment, integration of medical care and nursing, as well as early postoperative rehabilitation, joint care and exercise therapy and other services.
[0127] "IMV" stands for intermittent mandatory ventilation, which implements periodic volume or pressure ventilation based on a preset time interval, i.e., time trigger. During this period, the patient is allowed to breathe spontaneously at any set basal pressure level during mandatory ventilation. During spontaneous breathing, the patient can breathe spontaneously with continuous airflow support, or the machine will open the on-demand valve to allow spontaneous breathing. Most ventilators can provide pressure support during spontaneous breathing.
[0128] "HFNC" is high-flow nasal cannula oxygen therapy, which is an oxygen therapy method that directly delivers a certain oxygen concentration of air-oxygen mixed with high-flow gas to the patient through a nasal cannula without sealing. As a form of non-invasive respiratory support, it can quickly improve oxygenation. Currently, it can be applied to patients with acute hypoxic respiratory failure, postoperative patients, patients with respiratory failure who have not undergone endotracheal intubation, immunosuppressed patients, patients with heart failure, etc.
[0129] "NIV" refers to non-invasive ventilation, which refers to non-invasive mechanical ventilation other than endotracheal intubation and tracheotomy.
[0130] Novel Coronavirus (SARS-CoV-2)
[0131] As used herein, the terms "new coronavirus", "2019-nCov" or "SARS-CoV-2" are used interchangeably. The 2019 novel coronavirus is the seventh coronavirus known to infect humans and causes COVID-19, which is one of the serious infectious diseases threatening global human health.
[0132] Coronavirus (CoV) belongs to the Coronaviridae family of the Nidovirales order. It is an enveloped positive-strand RNA virus, and its subfamily includes four genera: α, β, δ, and γ. Among the currently known coronaviruses that infect humans, HCoV-229E and HCoV-NL63 belong to the α-coronavirus, and HCoV-OC43, SARS-CoV, HCoV-HKU1, MERS-CoV, and SARS-CoV-2 are all β-coronaviruses. SARS-CoV-2 is also known as 2019-nCov.
[0133] The genome of this type of virus is a single-stranded positive-strand RNA, which is one of the largest RNA viruses. It encodes replicase, spike protein, envelope protein, envelope protein and nucleocapsid protein, etc. In the initial stage of viral replication, the genome is translated into two peptide chains of several thousand amino acids, namely precursor polyproteins. Subsequently, the precursor proteins are cleaved by proteases to generate non-structural proteins (such as RNA polymerase and helicase) and structural proteins (such as spike protein) and auxiliary proteins.
[0134] Bispecific Antibodies
[0135] As used herein, the terms "bispecific antibody of the present invention", "bifunctional fusion antibody of the present invention", and "bispecific antibody against coronavirus RBD of the present invention" are used interchangeably and refer to a bispecific antibody that simultaneously binds to a first epitope and a second epitope targeting the SARS-CoV-2 RBD domain.
[0136] In the present invention, the bispecific antibody comprises:
[0137] A first targeting domain D1, which targets a first epitope of the SARS-CoV-2 RBD domain; and
[0138] A second targeting domain D2, which targets a second epitope of the SARS-CoV-2 RBD domain;
[0139] Wherein, the first epitope of the SARS-CoV-2 RBD domain has one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18) selected from the following sites in the RBD region of the S protein: 346R, 437N, 438S, 439N, 440N, 441L, 443S, 444K, 445V, 446G, 447G, 448N, 449Y, 450N, 498Q, 499P, 500T, 506Q;
[0140] The second epitope of the SARS-CoV-2 RBD domain has one or more (preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or 17) selected from the following sites in the RBD region of the S protein: 352A, 353W, 355R, 357R, 393T, 394N, 396Y, 462K, 463P, 464F, 465E, 466R, 468I, 516E, 518L, 519H, 520A.
[0141] In another preferred example, the first epitope and the second epitope do not overlap or substantially do not overlap.
[0142] In a preferred embodiment, the bispecific antibody of the present invention is a homodimer or a heterodimer; preferably a homodimer, having a structure shown in any one of formulas ad from the N-terminus to the C-terminus:
[0143] VH1-L1-VL2-L2-VH2-L3-VL1-L4-Fc type a
[0144] VL1-L1-VH2-L2-VL2-L3-VH1-L4-Fc type b
[0145] VH2-L1-VL1-L2-VH1-L3-VL2-L4-Fc type c
[0146] VL2-L1-VH1-L2-VL1-L3-VH2-L4-Fc formula d;
[0147] in,
[0148] VH1 is the first heavy chain variable region, VL1 is the first light chain variable region;
[0149] VH2 is the second heavy chain variable region, VL2 is the second light chain variable region;
[0150] L1, L2, L3, and L4 are each independently none, a bond, or a linker;
[0151] Fc is the Fc element;
[0152] “-” represents a peptide bond.
[0153] The bispecific antibodies of the present invention include not only complete antibodies, but also fragments of antibodies with immunological activity or fusion proteins formed by antibodies and other sequences. Therefore, the present invention also includes fragments, derivatives and analogs of the antibodies.
[0154] As used herein, the terms "fragment", "derivative" and "analog" refer to polypeptides that substantially retain the same biological function or activity as the antibodies of the present invention. The polypeptide fragments, derivatives or analogs of the present invention may be (i) polypeptides in which one or more conservative or non-conservative amino acid residues (preferably conservative amino acid residues) are substituted, and such substituted amino acid residues may or may not be encoded by the genetic code, or (ii) polypeptides having a substitution group in one or more amino acid residues, or (iii) polypeptides formed by fusion of a mature polypeptide with another compound (such as a compound that prolongs the half-life of the polypeptide, such as polyethylene glycol), or (iv) polypeptides formed by fusion of an additional amino acid sequence to the polypeptide sequence (such as a leader sequence or secretory sequence or a sequence or proprotein sequence used to purify the polypeptide, or a fusion protein formed with a 6His tag). According to the teachings herein, these fragments, derivatives and analogs are within the scope known to those skilled in the art.
[0155] The antigen binding fragments of the present invention include those that can specifically bind to coronavirus RBD. Examples of antibody binding fragments include, for example, but not limited to, Fab, Fab', F(ab')2, Fv fragments, single-chain Fv (scFv) fragments, and single domain fragments.
[0156] The "Fab" fragment consists of a light chain and the CH1 and variable regions of a heavy chain.
[0157] A "Fab'" fragment contains a light chain and a portion of a heavy chain including a VH domain, a CH1 domain, and a portion of the constant region between the CH1 and CH2 domains, with an interchain disulfide bond formed between the two heavy chains of two Fab' fragments to form a F(ab')2 molecule.
[0158] The "F(ab')2" fragment contains two light chains and portions of two heavy chains including a VH domain, a CH1 domain, and a portion of the constant region between the CH1 and CH2 domains, whereby an interchain disulfide bond is formed between the two heavy chains. Thus, the F(ab')2 fragment consists of two Fab' fragments held together by a disulfide bond between the two heavy chains.
[0159] The "Fv" fragment is the smallest fragment of an antibody containing a complete target recognition and binding site. This region is composed of a dimer (VH-VL dimer) of a heavy chain and a light chain variable domain in tight non-covalent binding. In this configuration, the three CDRs of each variable domain interact to define the target binding site on the surface of the VH-VL dimer. Typically, six CDRs confer target binding specificity to antibodies. However, in some cases, even a single variable domain (or only half of an Fv containing three CDRs specific for a target) can have the ability to recognize and bind to a target, although its affinity is lower than the entire binding site.
[0160] "Single-chain Fv" or "scFv" antibody binding fragments comprise the VH and VL domains of an antibody, wherein these domains are present in a single polypeptide chain. Typically, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains that enables the scFv to form a structure that is conducive to target binding.
[0161] A "single domain fragment" consists of a single VH or VL domain that exhibits sufficient affinity for coronavirus RBD. In a specific embodiment, the single domain fragment is camelized.
[0162] The bispecific antibodies against coronavirus RBD of the present invention include derivatized antibodies. For example, derivatized antibodies are usually modified by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protection / blocking groups, proteolytic cleavage, and connection to cell ligands or other proteins. Any of a number of chemical modifications can be performed by known techniques, including but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, and the like. In addition, the derivatives may contain one or more non-natural amino acids, for example, using ambrx technology.
[0163] The bispecific antibody of the present invention refers to an antibody having anti-SARS-CoV-2 activity and comprising two structures of any one of the above formulas ad. The term also includes variant forms of antibodies having the same function as the bispecific antibody of the present invention and comprising two structures of any one of the above formulas ad. These variant forms include (but are not limited to): one or more (usually 1-50, preferably 1-30, more preferably 1-20, and optimally 1-10) amino acid deletions, insertions and / or substitutions, and addition of one or several (usually within 20, preferably within 10, and more preferably within 5) amino acids at the C-terminus and / or N-terminus. For example, in the art, when amino acids with similar or similar properties are substituted, the function of the protein is generally not changed. For another example, adding one or several amino acids to the C-terminus and / or N-terminus generally does not change the function of the protein. The term also includes active fragments and active derivatives of the bispecific antibodies of the present invention.
[0164] Variant forms of the bispecific antibody include: homologous sequences, conservative variants, allelic variants, natural mutants, induced mutants, proteins encoded by DNA that can hybridize with the encoding DNA of the antibody of the present invention under high or low stringency conditions, and polypeptides or proteins obtained using antiserum against the antibody of the present invention.
[0165] In the present invention, "conservative variants of the bispecific antibody of the present invention" refer to polypeptides formed by replacing at most 10, preferably at most 8, more preferably at most 5, and most preferably at most 3 amino acids with amino acids having similar or similar properties compared to the amino acid sequence of the bispecific antibody of the present invention. These conservative variant polypeptides are preferably generated by amino acid substitution according to Table 1.
[0166] Table 1
[0167] Initial residue Representative replacement Preferred substitutions Ala(A) Val; Leu; Ile Val Arg(R) Lys; Gln; Asn Lys Asn(N) Gln; His; Lys; Arg Gln Asp(D) Glu Glu Cys(C) Ser Ser Gln(Q) Asn Asn Glu(E) Asp Asp Gly(G) Pro; Ala Ala His(H) Asn; Gln; Lys; Arg Arg Ile(I) Leu; Val; Met; Ala; Phe Leu Leu(L) Ile; Val; Met; Ala; Phe Ile Lys(K) Arg; Gln; Asn Arg Met(M) Leu; Phe; Ile Leu Phe(F) Leu; Val; Ile; Ala; Tyr Leu Pro(P) Ala Ala Ser(S) Thr Thr Thr(T) Ser Ser Trp(W) Tyr; Phe Tyr Tyr(Y) Trp; Phe; Thr; Ser Phe Val(V) Ile; Leu; Met; Phe; Ala Leu
[0168] Encoding nucleic acid and expression vector
[0169] The present invention also provides a polynucleotide molecule encoding the above-mentioned antibody or its fragment or its fusion protein. The polynucleotide of the present invention can be in the form of DNA or RNA. The DNA form includes cDNA, genomic DNA or artificially synthesized DNA. The DNA can be single-stranded or double-stranded. The DNA can be a coding strand or a non-coding strand.
[0170] The polynucleotide encoding the mature polypeptide of the present invention includes: a coding sequence encoding only a mature polypeptide; a coding sequence of a mature polypeptide and various additional coding sequences; a coding sequence of a mature polypeptide (and optional additional coding sequences) and non-coding sequences.
[0171] The term "polynucleotide encoding a polypeptide" may include a polynucleotide encoding the polypeptide, or may include additional coding and / or non-coding sequences.
[0172] The nucleic acids (and nucleic acid combinations) of the present invention can be used to produce the recombinant antibodies of the present invention in a suitable expression system.
[0173] The present invention also relates to polynucleotides that hybridize with the above sequences and have at least 50%, preferably at least 70%, and more preferably at least 80% identity between the two sequences. The present invention particularly relates to polynucleotides that can hybridize with the polynucleotides of the present invention under stringent conditions. In the present invention, "stringent conditions" refer to: (1) hybridization and elution at relatively low ionic strength and relatively high temperature, such as 0.2×SSC, 0.1% SDS, 60°C; or (2) addition of denaturing agents during hybridization, such as 50% (v / v) formamide, 0.1% calf serum / 0.1% Ficoll, 42°C, etc.; or (3) hybridization occurs only when the identity between the two sequences is at least 90%, preferably at least 95%. In addition, the polypeptide encoded by the hybridizable polynucleotide has the same biological function and activity as the mature polypeptide.
[0174] The full-length nucleotide sequence of the antibody of the present invention or its fragment can usually be obtained by PCR amplification, recombination or artificial synthesis. A feasible method is to synthesize the relevant sequence by artificial synthesis, especially when the fragment length is short. Usually, a fragment with a very long sequence can be obtained by synthesizing multiple small fragments first and then connecting them. In addition, the coding sequence of the heavy chain and the expression tag (such as 6His) can be fused together to form a fusion protein.
[0175] Once the relevant sequence is obtained, it can be obtained in large quantities by recombinant methods. This is usually done by cloning it into a vector, then transferring it into cells, and then isolating the relevant sequence from the proliferated host cells by conventional methods. The biomolecules (nucleic acids, proteins, etc.) involved in the present invention include biomolecules in isolated form.
[0176] At present, the DNA sequence encoding the protein of the present invention (or its fragment, or its derivative) can be obtained completely by chemical synthesis. The DNA sequence can then be introduced into various existing DNA molecules (or vectors) and cells known in the art. In addition, mutations can also be introduced into the protein sequence of the present invention by chemical synthesis.
[0177] The present invention also relates to vectors comprising the above-mentioned appropriate DNA sequence and appropriate promoter or control sequence. These vectors can be used to transform appropriate host cells to enable them to express proteins.
[0178] Host cells can be prokaryotic cells, such as bacterial cells; or lower eukaryotic cells, such as yeast cells; or higher eukaryotic cells, such as mammalian cells. Representative examples include: Escherichia coli, Streptomyces; bacterial cells of Salmonella typhimurium; fungal cells such as yeast; insect cells of Drosophila S2 or Sf9; animal cells such as CHO, COS7, 293 cells, etc.
[0179] Transformation of host cells with recombinant DNA can be carried out using conventional techniques well known to those skilled in the art. When the host is a prokaryotic organism such as Escherichia coli, competent cells that can absorb DNA can be harvested after the exponential growth phase and treated with the CaCl2 method, the steps used are well known in the art. Another method is to use MgCl2. If necessary, transformation can also be carried out by electroporation. When the host is a eukaryotic organism, the following DNA transfection methods can be selected: calcium phosphate coprecipitation method, conventional mechanical methods such as microinjection, electroporation, liposome packaging, etc.
[0180] The obtained transformant can be cultured by conventional methods to express the polypeptide encoded by the gene of the present invention. Depending on the host cell used, the culture medium used in the culture can be selected from various conventional culture media. Culture is carried out under conditions suitable for the growth of the host cells. After the host cells grow to an appropriate cell density, the selected promoter is induced by a suitable method (such as temperature conversion or chemical induction), and the cells are cultured for a period of time.
[0181] The recombinant polypeptide in the above method can be expressed in the cell, on the cell membrane, or secreted outside the cell. If necessary, the recombinant protein can be separated and purified by various separation methods using its physical, chemical and other properties. These methods are well known to those skilled in the art. Examples of these methods include but are not limited to: conventional renaturation treatment, treatment with a protein precipitant (salting out method), centrifugation, osmotic sterilization, ultra-treatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography techniques and combinations of these methods.
[0182] The bispecific antibodies of the invention can be used alone or in combination or conjugated with a detectable marker (for diagnostic purposes), a therapeutic agent, or any combination of these.
[0183] Detectable labels for diagnostic purposes include, but are not limited to, fluorescent or luminescent labels, radioactive labels, MRI (magnetic resonance imaging) or CT (computed tomography) contrast agents, or enzymes capable of producing a detectable product.
[0184] Therapeutic agents that can be combined or coupled with the antibodies of the present invention include, but are not limited to: 1. Radionuclides; 2. Biological toxins; 3. Cytokines such as IL-2; 4. Gold nanoparticles / nanorods; 5. Viral particles; 6. Liposomes; 7. Nanomagnetic particles; 8. Drugs for neutralizing viruses, including but not limited to: Favipiravir, Remdesivir or interferon, etc.
[0185] Pharmaceutical composition
[0186] The dosage of the active ingredient of the pharmaceutical composition of the present invention varies depending on the subject of administration, the subject organ, symptoms, the method of administration, etc., and can be determined based on the doctor's judgment in consideration of the type of dosage form, the method of administration, the age and weight of the patient, the patient's symptoms, etc.
[0187] The pharmaceutical composition of the present invention contains the bispecific antibody or its active fragment or its fusion protein described above, and a pharmaceutically acceptable carrier. Generally, these substances can be formulated in a non-toxic, inert and pharmaceutically acceptable aqueous carrier medium, wherein the pH is generally about 5-8, preferably about 6-8, although the pH value may vary with the nature of the formulated substance and the condition to be treated. The formulated pharmaceutical composition can be administered by conventional routes, including (but not limited to): intravenous injection, intravenous drip, subcutaneous injection, local injection, intramuscular injection, intratumor injection, intraperitoneal injection (such as intraperitoneal), intracranial injection, intracavity injection or intranasal administration (such as nasal spray administration). In particular, the pharmaceutical composition described herein can be formulated for intranasal administration or administration by another local route, such as administration to a biological surface, including, for example, a mucous membrane or skin. Drug carriers suitable for facilitating this mode of administration are well known in the art.
[0188] Preferably, the pharmaceutical composition of the present invention further comprises other pharmaceutically active agents, such as other antiviral agents, preferably favipiravir, remdesivir or interferon.
[0189] Specifically, a nasal spray containing 0.001% or 0.15% (w / w) azelastine compound in an aqueous solution at pH 6.8±0.3 can be used, optionally further containing any one or more of citric acid monohydrate, disodium hydrogen phosphate dodecahydrate, edetate disodium, hydroxypropyl methylcellulose, purified water, sodium chloride, benzalkonium chloride and other preservatives.
[0190] As used herein, the term "mucosal" with respect to the administration or application of a formulation for treating a subject or corresponding formulation or other mucosal use, refers to administration by a mucosal route, including systemic or topical administration, wherein the active ingredient is absorbed by contact with a mucosal surface. This includes nasal, pulmonary, oral or oral administration and formulations such as liquids, syrups, lozenges, eye drops, tablets, sprays, powders, instant powders, granules, capsules, creams, gels, drops, suspensions or emulsions.
[0191] The bispecific antibodies or antigen-binding fragments thereof of the invention or the pharmaceutical compositions of the invention can be administered to a subject by any appropriate route of administration, including, but not limited to, oral, buccal, sublingual, topical, parenteral, rectal, intrathecal, or nasal routes.
[0192] As used herein, the term "parenteral" refers to administration routes including intravenous, intramuscular, intranasal, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion. The administration route may be systemic or local.
[0193] As used herein, the "safe and effective amount" may vary depending on the subject of administration, the subject's organ, symptoms, administration method, etc., and may be determined based on the doctor's judgment, taking into account the type of dosage form, administration method, patient's age and weight, patient's symptoms, etc.
[0194] The pharmaceutical composition of the present invention contains a safe and effective amount (such as 0.001-99wt%, preferably 0.01-90wt%, more preferably 0.1-80wt%) of the above-mentioned bispecific antibody (or its conjugate) of the present invention and a pharmaceutically acceptable carrier or excipient. Such carriers include (but are not limited to): saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof. The pharmaceutical preparation should match the mode of administration. The pharmaceutical composition of the present invention can be prepared in the form of an injection, for example, by conventional methods using physiological saline or an aqueous solution containing glucose and other adjuvants. Pharmaceutical compositions such as injections and solutions are preferably manufactured under sterile conditions. The dosage of the active ingredient is a therapeutically effective amount, for example, about 10 micrograms / kg body weight to about 50 milligrams / kg body weight per day. In addition, the polypeptide of the present invention can also be used with other therapeutic agents.
[0195] When using a pharmaceutical composition, a safe and effective amount of the immunoconjugate is administered to a mammal, wherein the safe and effective amount is usually at least about 10 micrograms / kg body weight, and in most cases does not exceed about 50 milligrams / kg body weight, preferably the dosage is about 10 micrograms / kg body weight to about 10 milligrams / kg body weight. Of course, the specific dosage should also take into account factors such as the route of administration and the patient's health status, which are all within the skill range of skilled physicians.
[0196] Combination therapy
[0197] In some embodiments, the bispecific antibodies of the present invention can be used in conjunction with other treatment or prevention regimens, including administration of one or more antiviral antibodies and one or more other therapeutic agents or methods. For combined therapy, the bispecific antibodies of the present invention can be administered simultaneously or separately with other therapeutic agents. When administered separately, the bispecific antibodies of the present invention can be administered before or after administration of another other therapeutic agent.
[0198] In some embodiments, the therapeutic agent used in combination with the bispecific antibody of the present invention is one of the following: HIV drugs, antimalarial drugs, RNA polymerase inhibitors, antiviral drugs and monoclonal antibodies. In some embodiments, HIV drugs include lopinavir / ritonavir, ASC09 / ritonavir and darunavir; lopinavir / ritonavir and ribavirin alone are not recommended. In some embodiments, antimalarial drugs include chloroquine phosphate. In some embodiments, antiviral drugs include arbidol, favipiravir and α-interferon. In some embodiments, monoclonal antibodies include BDB-001.
[0199] Some patients with severe or critical COVID-19 infection experience cytokine storms. The antibodies of the present invention can be combined with adalimumab (e.g., adalimumab and its biosimilars, such as Abrilada TM (adalimumab-afzb), Amjevita (adalimumab-att), Cyltezo TM (adalimumab-adbm), Hyrimoz TM (adalimumab-adaz), Hulio TM , (BAT1406)) or tochilizumab (for example and its biosimilars, such as BAT1806) are used in combination for treatment, which can slow down the inflammatory response caused by upregulated TNF-α expression. In some embodiments, the patient treated by this method is diagnosed with infection with the new coronavirus and has one or more cytokines (including tumor necrosis factor α (TNF-α), IFN-γ, IL-1β, IL-2, IL-4, IL-7, IL-8, IL-10, IL-12p70, IL-13, granulocyte colony stimulating factor (GSCF), interferon-induced protein-10 (IP-10), monocyte chemoattractant protein-1 (MCP1), macrophage inflammatory protein 1α (MIP1A)). In some embodiments, the patient treated by this method has increased TNF-α. In some embodiments, one or more cytokines are at least 50% higher than normal levels. In some embodiments, one or more cytokines are at least 2 times, 3 times, or 4 times the normal level. In some embodiments, the patient has fever, hypotension, hypoxia, and / or acute respiratory distress syndrome (ARDS) before treatment with this method. In some embodiments, the patient has lungs filled with inflammatory fluid (so-called "white lung") before treatment with this method. In some embodiments, the patient has cytokine release syndrome (CRS) caused by cytokine storm before treatment with this method.
[0200] In some embodiments, the bispecific antibodies of the present invention are used in combination with ICU treatment. In some embodiments, the bispecific antibodies of the present invention are combined with extracorporeal ECMO and / or IMV treatment. In some embodiments, the bispecific antibodies of the present invention are combined with oxygen therapy. In some embodiments, the bispecific antibodies of the present invention are combined with NIV / HFNC treatment. In some embodiments, after treatment, one or more cytokines of the patient are at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% lower than before treatment. In some embodiments, the method allows the patient to recover.
[0201] application
[0202] The present invention also provides diagnostic methods and uses. In some embodiments, a method for detecting the expression of SARS-CoV-2 in a sample is provided, wherein the sample is contacted with the antibody so that the antibody binds to the spike protein, and the binding is detected, that is, the content of the spike protein in the sample. The present invention provides a bispecific antibody targeting coronavirus and its application, wherein the first targeting domain and the second targeting domain in the bispecific antibody synergistically prevent SARS-CoV-2 virus particles from infecting cells, and mediate immune cell phagocytosis and clearance of virus particles, and prevent, treat or improve COVID-19; the bispecific antibody of the present invention can also be used to diagnose whether a patient is infected with SARS-CoV-2. In some embodiments, the use of the antibody in the preparation of a kit for diagnosing COVID-19 or for SARS-CoV-2 antigen detection is provided. In some embodiments, a diagnostic kit comprising the bispecific antibody is provided.
[0203] The present invention also provides treatment methods and uses. In some embodiments, a method for preventing, treating or improving COVID-19 is provided, the method comprising administering an effective dose of the bispecific antibody of the present invention to a patient. In some embodiments, the use of the bispecific antibody in preventing, treating or improving COVID-19 is provided. In some embodiments, the use of the bispecific antibody in the preparation of a medicament for preventing, treating or improving COVID-19 is provided. In some embodiments, the patient is a patient suspected of being infected with the SARS-CoV-2 virus. In some embodiments, the patient is a patient who has been in contact with a SARS-CoV-2 virus carrier. In some embodiments, the patient is a patient diagnosed with SARS-CoV-2 virus infection. In some embodiments, the patient is a patient with mild symptoms. In some embodiments, the patient is a patient with severe symptoms. In some embodiments, the patient has fever, cough, hypotension, hypoxia, and / or acute respiratory distress syndrome (ARDS).
[0204] The specific dosage and treatment regimen for any particular patient will depend on various factors, including the antibody used, the patient's age and weight, general health, sex and diet, as well as the time of administration, frequency of excretion, drug combination, and the severity of the specific disease being treated. These factors are judged by medical care personnel included within the scope of ordinary technicians in the field. The dosage will also depend on the individual patient to be treated, the route of administration, the type of formulation, the characteristics of the compound used, the severity of the disease, and the desired effect. The dosage used can be determined by pharmacological and pharmacokinetic principles well known in the art.
[0205] The main advantages of the present invention include
[0206] (1) The bispecific antibody of the present invention has broad-spectrum neutralizing activity and has good neutralizing ability against pseudoviruses of the current COVID-19 strains. Its broad-spectrum ability and neutralizing ability are better than those of the positive control LY-CoV1404, the parental monoclonal antibody, and the combination of the parental monoclonal antibodies (Cocktail therapy, i.e., the combination of 65 monoclonal antibodies and 56 monoclonal antibodies).
[0207] (2) The bispecific antibody of the present invention can effectively inhibit SARS-CoV-2 pseudovirus infection and also has good neutralizing activity against real viruses. The bispecific antibody of the present invention has application value in clinical treatment and prevention of SARS-CoV-2 infection.
[0208] (3) The bispecific antibody of the present invention can effectively inhibit the replication of SAR-CoV-2 strains in the lungs, nasal cavity and brain of transgenic mice, and has good preventive and therapeutic protective effects on mice. The present invention provides a potential new antibody drug for the clinical prevention, treatment and detection of new coronaviruses
[0209] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods for which detailed conditions are not indicated in the following examples are generally performed under conventional conditions such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or under conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.
[0210] Example 1. Construction of bispecific antibody protein molecules
[0211] Using the method disclosed in Chinese patent applications CN202211588062.X and CN202211538937.5, two non-competitive ultra-broad-spectrum fully human monoclonal antibodies CoV56 and L4.65 were isolated from the bodies of people immunized with the new crown recombinant protein vaccine, and the light and heavy chain variable regions of CoV56 monoclonal antibody (abbreviated as 56 monoclonal antibody or 56IgG) and L4.65 monoclonal antibody (abbreviated as 65 monoclonal antibody or 65IgG) were arranged in different orders, and after adding L234A and L235A mutations, they were connected in series with FCtaq ( Figure 1A ), bispecific antibody proteins DIA-19 (SEQ ID NO.1), DIA-20 (SEQ ID NO.2), DIA-21 (SEQ ID NO.3) and DIA-22 (SEQ ID NO.4) were constructed, and their structures are as follows Figure 1B shown.
[0212] In addition, based on the structure of DIA-19, a bispecific antibody protein DIA-23 (SEQ ID NO. 27) with M252Y / S254T / T256E mutations in the Fc region was further constructed to prolong the half-life of the bispecific antibody.
[0213] The seven-category classification method of Hastie KM, et al (see Hastie KM, et al: Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. Science 2021, 374 (6566): 472-478) was adopted to determine the binding epitopes of the 65 monoclonal antibodies and the 56 monoclonal antibodies in the present invention (such as Figure 1C shown).
[0214] The experiments showed that the 65 monoclonal antibody binding epitope is in the RBD5 region of the S protein. The specific sites are 2019-nCov: 346R, 437N, 438S, 439N, 440N, 441L, 443S, 444K, 445V, 446G, 447G, 448N, 449Y, 450N, 498Q, 499P, 500T and 506Q.
[0215] By analyzing the crystal structure of the complex of 56 monoclonal antibody and SARS-CoV-2 RBD, the RBD epitope recognized by 56 antibody was obtained. The binding epitope of 56 monoclonal antibody is in the RBD region of S protein different from the binding epitope of 65 monoclonal antibody. The specific sites are 2019-nCov: 352A, 353W, 355R, 357R, 393T, 394N, 396Y, 462K, 463P, 464F, 465E, 466R, 468I, 516E, 518L, 519H and 520A.
[0216] The binding epitopes of mAb 65 and mAb 56 are located at non-overlapping positions in the RBD region, and the RBD region bound by mAb 56 is relatively conservative.
[0217] Example 2. ELISA to determine the binding ability of anti-novel coronavirus bispecific antibodies to RBD of various novel coronavirus strains
[0218] The RBD protein (2019-nCoV, BA.1.1, BA.2.12.1, BA.5, XBB, BF.7, BQ.1.1) was diluted to 1 μg / mL with coating buffer, and 100 μL / well was added to the ELISA plate, and it was kept at 4°C overnight; the plate was washed 3 times with PBST, and 300 μL / well blocking solution was added, and it was placed at room temperature for 2 hours, and then the plate was washed 3 times with PBST for use. The bispecific antibody was diluted with diluent, and the starting concentration was 200 nM (BA.1.1, BA.2.12.1 and XBB), 100 nM (BQ.1.1), 50 nM (BF.7) or 30 nM (2019-nCoV and BA.5), and 4-fold dilution was used to form 8 concentration gradients, and then added to the blocked ELISA plate in sequence, 100 μL / well, and placed at 37°C for 2 hours. Wash the plate 3 times with PBST, add HRP-labeled mouse anti-human Fc antibody (1:3000), 100 μL / well, and place at 37°C for 1 hour. After washing the plate 3 times with PBST, pat dry the residual droplets on absorbent paper as much as possible, add 100 μL of TMB to each well, and place it at room temperature (20±5°C) away from light for 5 minutes; add 70 μL of 2MH2SO4 stop solution to each well to stop the substrate reaction, read the OD value at 450nm with an enzyme reader, and perform data analysis with GraphPadPrism9, plot and calculate EC 50 .
[0219] Figure 2A-2G The results show that the bispecific antibodies and monoclonal antibodies against the novel coronavirus can bind to the RBD of various novel coronavirus strains. Figure 2A-2D As shown, the anti-COVID-19 bispecific antibodies DIA-19, DIA-20, DIA-21, DIA-22 and parental monoclonal antibodies 65 and 56 can all bind to the S protein RBD of the 2019 original strain (2019-nCoV), BA.1.1, BA.2.12.1 and BA.5 strains in a concentration-dependent manner with comparable affinity.
[0220] Figure 2E-2G The results showed that DIA-19 binds to the S protein RBD of BF.7, BQ1.1 and XBB strains in a concentration-dependent manner. The control drug antibody Eli Lilly's LY-CoV1404 can bind to the BF.7 strain in a concentration-dependent manner, but for the dominant strains BQ.1.1 and XBB in the United States and Singapore recently, LY-CoV1404 has obviously lost its binding ability.
[0221] Example 3. Determination of the affinity dissociation constant KD of the anti-new coronavirus bispecific antibody DIA-19 for the spike / RBD proteins of four new coronaviruses (BA.5, BF.7, BQ.1.1, XBB)
[0222] DIA-19 and LY-CoV1404 were captured using a chip covalently coupled with ProteinA, with a concentration of 2 μg / mL, a contact time of 60 s, a flow rate of 10 μL / min, and a regeneration contact time of 30 s. Antigens SARS-CoV-2 (BA.5) SpikeRBD, SARS-CoV-2 (BF.7) SpikeRBD, SARS-CoV-2 BQ.1.1 (Omicron) SpikeRBD, and SARS-CoV-2 XBB (Omicron) SpikeRBD were diluted with HBS-N pH 7.4 buffer, with the highest concentrations of 12.5 nM, 6.25 nM, 25 nM, and 6.25 nM, respectively. Six concentration gradients were diluted in a 2-fold gradient, and a 0 concentration point was set. A 6 M guanidine hydrochloride solution was used as the regeneration buffer, and the sample was injected on Biacore 8K according to the following parameters: binding time 120 s, dissociation time 600 s, flow rate 60 μL / min, and regeneration contact time 30 s. Repeat the next cycle. The data were analyzed using Biacore8KEvaluationSoftware, as shown in Table 2.
[0223] The experimental results showed that DIA-19 can bind to the RBD of BA.5, BF.7, BQ.1.1 and XBB with high affinity, with KD values of 3.59E-11M, 4.50E-11M, 2.03E-10M and 8.11E-11M, respectively. The affinity of LY-CoV1404 to the RBD of BA.5 and BF.7 is weaker than that of DIA-19, with KD values of 1.84E-10M and 1.62E-10M, respectively, and there is no binding signal with BQ.1.1 and XBB.
[0224] Table 2 Affinity parameters of DIA-19 and each subtype of OMICRON RBD
[0225]
[0226] Note: / indicates no binding signal.
[0227] Example 4. Neutralization experiment of anti-new coronavirus bispecific antibody DIA-19 against new coronavirus variant pseudovirus
[0228] The SARS-CoV-2 bispecific antibody DIA-19 can block the virus infection by binding to the SARS-CoV-2 S protein. Here, the ability of DIA-19 to block the biological activity of SARS-CoV-2 variants was evaluated using a pseudovirus model expressing the S protein on the VSV virus.
[0229] Vero cells in good condition were plated in 96-well cell plates and cultured overnight at 37°C and 5% CO2. Antibodies were diluted to a concentration of 1000 ng / mL with DMEM medium, and the antibodies were diluted in a 3-fold concentration gradient. The virus solution diluted with DMEM medium was added to the gradient diluted antibodies at a volume ratio of 1:1, and the cells were incubated at 37°C for 1 hour. The Vero cell supernatant was discarded, and 100 μL of the antibody-virus mixture was added to the cell plate. After culturing at 37°C and 5% CO2 for 16 hours, the green fluorescence points were read with high-content CQ1. Data were analyzed using Excel and GraphPadPrism6, and graphs were drawn and IC was calculated. 50 .
[0230] The experimental results are as follows Figure 3 And as shown in Table 3. Figure 3 Indications: Infection rate curves and IC values of DIA-19, parental monoclonal antibody, cocktail therapy (combination of parental monoclonal antibodies 65 and 56), and control antibody LY-CoV1404 against different novel coronavirus mutant strains 50 The experimental results show that DIA-19 has good neutralizing ability against pseudoviruses of the current COVID-19 strains. Its broad-spectrum ability and neutralizing ability against COVID-19 strains are significantly better than the parent monoclonal antibodies 65 (i.e. L4.65) and 56 (i.e. Cov56), significantly better than the combination of monoclonal antibodies 65 and 56, and significantly better than the control antibody LY-CoV1404.
[0231] Table 3 Neutralization activity of DIA-19 against different mutant strains of novel coronavirus (IC 50 Value ng / mL)
[0232] <![CDATA[IC 50 (ng / ml)]]> Prototype Delta BA.1 BA.2.75 BA.4 / 5 BF.7 BQ.1 BQ.1.1 XBB XBB.1.5 L4.65 0.9695 2.522 1.353 11.15 1.384 2.123 >2000 >2000 21.4 54.12 CoV56 >2000 >2000 >2000 >2000 >2000 >2000 >2000 >2000 >2000 >2000 Cocktail 2.006 4.607 1.992 16.91 2.423 3.819 >2000 >2000 35.64 67.18 DIA-19 0.7336 1.344 0.4233 1.759 0.8586 1.192 6.822 46.62 1.939 1.661 LY-CoV1404 1.187 3.046 1.439 25.1 1.219 2.136 >2000 >2000 >2000 >2000
[0233] Similar experiments were conducted on the remaining DIA-20-DIA-23, and all showed good neutralizing ability against pseudoviruses of the current COVID-19 epidemic strain.
[0234] Example 5. Neutralization experiment of anti-COVID-19 bispecific antibody DIA-19 against live virus of COVID-19 variant
[0235] In order to verify the neutralizing activity of DIA-1.9 against live coronavirus variants, Huawu Biotechnology (Hubei) Co., Ltd. and the Institute of Viral Diseases (P3 laboratory) of the National Center for Disease Control and Prevention were commissioned to conduct live virus neutralization experiments.
[0236] African green monkey kidney passage cells (VERO-E6) were plated and cultured in a 37°C 5% CO2 incubator until they were monolayers. Before entering the BSL-3 and inoculating the virus, the cell culture medium was discarded and washed once with Hanks solution. The antibody was diluted to a concentration of 150 ng / mL with DMEM medium, and the antibody was diluted in a 3-fold concentration gradient; the virus was diluted to 200 TCID with DMEM maintenance medium 50 / 0.1mL, add 0.24mL of virus dilution (200TCID 50 / 0.1mL), mix well with equal volumes, seal with sealing film and incubate at 37°C for 1 hour. The virus control is 0.24mL of virus dilution (200TCID50 / 0.1mL) plus 0.24mL of maintenance solution, which is also sealed with sealing film and incubated at 37°C for 1 hour. The normal cell control does not add virus, but only contains DMEM maintenance solution. Discard the Hanks solution in the cell culture wells. Inoculate the antibody-virus mixture of each dilution in the 96-well deep well plate onto the monolayer cells, inoculate 4 wells for each dilution, 0.1mL per well, so that the amount of virus in each well is 100TCID50. Place the 96-well culture plate with the inoculated sample in a 37°C 5% CO2 incubator for culture. After the test samples and viruses were cultured on the cells for 3 days, the cell activity was detected using the CellTiterGlo chemiluminescent live cell detection kit. 50 μL CellTiter-Glo reagent was added to each well of a white 96-well plate, and then the microplate was gently shaken and mixed for 2 minutes on an oscillator, incubated at room temperature for 10 minutes, and the reading of each test well was detected by a LumiStation 1800 chemiluminescent microplate reader. GraphPad Prism 9 was used for data analysis, plotting, and calculation of IC 50 .
[0237] Figure 4A-4G The experiment of DIA-19 and positive control antibody LY-CoV1404 neutralizing live virus infection of multiple new coronavirus strains is shown. The experimental results show that the DIA-19 molecule can effectively block all strains tested so far, including 2019-PT (2019-nCov or PT), Delta, BA.5.2, and the latest BF.7, BQ.1, BQ.1.1 and XBB live viruses from infecting host cells. However, LY-CoV1404 cannot block the infection of host cells by BQ.1 live virus, nor can it block the infection of host cells by BQ.1.1 live virus and XBB live virus, indicating that the broad-spectrum neutralization ability of DIA-19 is significantly better than that of the control antibody LY-CoV1404.
[0238] Example 6. Neutralization effect of antibody DIA-19 on SARS-CoV-2 pseudovirus at the cellular level
[0239] Vero cells were infected with SARS-CoV-2 pseudovirus (artificially synthesized recombinant virus) in vitro, and the inhibitory effect of different concentrations of antibodies on the pseudoviruses of the prototype strain of the new coronavirus and different mutant strains of the new coronavirus (PT, BA.1, BA.1.1, BA.2, BA.2.75, BA.3, BA.4 / 5, BF.7, BQ.1, BQ.1.1, XBB, XBB.1.5, XBB.1.16) on the infection of Vero cells was measured, thereby detecting the in vitro broad-spectrum neutralizing activity of the new coronavirus neutralizing antibodies against different new coronavirus pseudoviruses. In this experiment, Vero cells were cultured at 1×10 4 cells / well for 96-well plating, incubated in a carbon dioxide cell culture incubator at 37°C for 24 hours, the antibody diluted with DMEM medium was thoroughly mixed with the SARS-CoV-2 virus, and the mixture was added to the paved cell wells after incubation at 37°C for 1 hour. The above 96-well plate was placed in a cell culture incubator (37°C, 5% CO2) and incubated for 16 hours. After 16 hours, the 96-well plate was taken out and read using a CQ1 high-speed laser confocal high-content flow cytometer, and the inhibitory effect of different antibody concentrations on pseudovirus-infected cells was calculated based on the GFP fluorescence number.
[0240] According to the results of neutralization inhibition rate at different concentrations, IC was calculated using biostatistics software Graphpad. 50 The results of the pseudovirus neutralization experiments of 56IgG, 65IgG, 56IgG+65IgG and DIA-19 are shown in Table 4.
[0241] Table 4 Neutralization effect of different forms of antibodies on SARS-CoV-2 pseudovirus (IC 50 μg / mL)
[0242] <![CDATA[IC 50 ]]> PT BA.1 BA.1.1 BA.2 BA.2.75 BA.3 BA.4 / 5 56 8.375 14.79 10.82 8.316 58.81 18.5 7.529 65 0.0007093 0.000394 0.0002797 0.0003897 0.001945 0.0004398 0.0003769 65+56 0.001683 0.0006741 0.000603 0.0006991 0.005084 0.0007861 0.0008157 DIA-19 0.0008494 0.0002719 0.0001819 0.0003768 0.001008 0.0003112 0.000332 <![CDATA[IC 50 ]]> BF.7 BQ.1 BQ.1.1 XBB XBB.1.5 XBB.1.16 56 11.72 19.63 15.91 15.86 11.83 21.73 65 0.0004464 2.093 4.584 0.003353 0.0137 0.01033 65+56 0.001009 21.4 37.81 0.007901 0.02487 0.05015 DIA-19 0.0004507 0.003138 0.007511 0.000652 0.000899 0.00072
[0243] The experimental results show that compared with the 56IgG+65IgG Cocktail method, the bispecific antibody of DIA-19 can show a better neutralization effect on the SARS-CoV-2 pseudovirus. In particular, in the BQ.1 and BQ.1.1 pseudovirus experiments, the neutralization effect of DIA-19 is more than 1000 times that of the cocktail method; the neutralization effect of DIA-19 on XBB, XBB.1.5 and XBB.1.16 is more than 10 times higher than that of the cocktail method.
[0244] Example 7. Neutralization effect of antibody DIA-19 on SARS-CoV-2EG.5 mutant pseudovirus at the cellular level
[0245] Vero cells were infected with SARS-CoV-2 EG.5 mutant pseudovirus (artificially synthesized recombinant virus) in vitro, and the inhibitory effect of different concentrations of antibodies on the infection of Vero cells by the SARS-CoV-2 EG.5 mutant pseudovirus was measured, thereby detecting the in vitro broad-spectrum neutralizing activity of the SARS-CoV-2 neutralizing antibodies against different SARS-CoV-2 pseudoviruses. In this experiment, Vero cells were cultured at a rate of 1×10 4 cells / well for 96-well plating, incubated in a carbon dioxide cell culture incubator at 37°C for 24 hours, the antibody diluted with DMEM medium was thoroughly mixed with the SARS-CoV-2 virus, and the mixture was added to the paved cell wells after incubation at 37°C for 1 hour. The above 96-well plate was placed in a cell culture incubator (37°C, 5% CO2) and incubated for 16 hours. After 16 hours, the 96-well plate was taken out and read using a CQ1 high-speed laser confocal high-content flow cytometer, and the inhibitory effect of different antibody concentrations on pseudovirus-infected cells was calculated based on the GFP fluorescence number.
[0246] The results of the pseudovirus neutralization experiments of 56IgG, 65IgG, 56IgG+65IgG and DIA-19 are shown in Tables 5 and Figure 5 shown.
[0247] Table 5 Neutralization effect of different forms of antibodies on SARS-CoV-2EG.5 mutant pseudovirus (IC 50 μg / mL)
[0248] 56IgG 65IgG 56IgG+65IgG DIA-19 <![CDATA[IC 50 ]]> 13.58 0.05212 0.05634 0.001147
[0249] The experimental results showed that compared with the 56IgG+65IgG Cocktail method, the bispecific antibody of DIA-19 was able to show a better neutralizing effect against the SARS-CoV-2EG.5 mutant pseudovirus. The neutralizing effect of DIA-19 against EG.5 was about 50 times higher than that of the Cocktail method.
[0250] Example 8. Study on the inhibitory effect of antibody DIA-19 on novel coronavirus XBB strain in mice
[0251] The purpose of this experiment is to determine the preventive and protective effect of the candidate antibody DIA-19 against the SARS-CoV-2XBB strain in a mouse infection model. The experiment used 6-8 week old K18-hACE2 transgenic mice to evaluate the virus clearance effect of the candidate antibody DIA-19 in the nasal cavity and lungs of experimental mice after preventive administration. A total of 30 mice were set up in the prevention experiment, divided into 5 groups, with 6 animals in each group, namely: 1mg / kg DIA-19 prevention group (low dose), 5mg / kg DIA-19 prevention group (medium dose), 20mg / kg DIA-19 prevention group (high dose), 20mg / kg LY-cov1404 prevention group, and 20mg / kg irrelevant antibody control group. Six hours after the antibody was administered intranasally (in), K18-hACE2 mice were infected with 2×10 3 TCID50 of SARS-CoV-2XBB strain. The viral load (viral gene copy number) and pathological symptoms in the lungs and nasal cavity of mice in the prevention group were tested on the third day after infection.
[0252] The experiment recorded the weight of mice on the day of infection with SARS-CoV-2XBB strain (Day 0) and on the third day after infection. Fig. 6A shown.
[0253] According to statistical analysis, the groups that were given 1mg / kg DIA-19, 5mg / kg DIA-19 and 20mg / kg DIA-19 by intranasal drops for prevention showed significantly lower lung viral gRNA and sgRNA loads compared with the unrelated antibody control group on day 3 of viral infection (as shown in 6B), with statistically significant differences; the average lung viral gRNA loads were reduced by 1.16, 1.16 and 1.82log10copies / g, respectively (as shown in Table 6); the average lung viral sgRNA loads were reduced by 1.95, 2.20 and 2.54log10copies / g, respectively (as shown in Table 8). However, there was no statistical difference in lung gRNA and sgRNA loads between the control antibody LY-cov1404 prevention group and the unrelated antibody control group.
[0254] According to statistical analysis, the nasal administration of 5mg / kg DIA-19 and 20mg / kg DIA-19 groups by intranasal drops on day 3 of virus infection significantly reduced the load of viral gRNA and sgRNA in the nasal cavity compared with the unrelated antibody control group (such as Figure 6BThe average viral gRNA load in the nasal cavity decreased by 2.20 and 2.50log10 copies / g, respectively (as shown in Table 7); the average viral sgRNA load in the nasal cavity decreased by 2.18 and 2.76log10 copies / g, respectively (as shown in Table 9). However, there was no statistical difference in the viral gRNA and sgRNA load in the nasal cavity compared with the unrelated antibody control group in the 1mg / kgDIA-19 prevention group and the control antibody LY-cov1404 prevention group.
[0255] The above results indicate that preventive administration of DIA-19 via nasal drops can effectively inhibit the replication of SARS-CoV-2XBB strain in the lungs and nasal cavity of transgenic mice, and has a good protective effect on mice.
[0256] Table 6 Virus load in mouse lungs on day 3 after SARS-CoV-2 infection in the prevention trial (gRNA)
[0257]
[0258] Note: “——” indicates that the mouse died due to factors other than antibodies or viruses, such as choking or overdose of anesthesia.
[0259] Table 7 Nasal viral load in mice on day 3 after SARS-CoV-2 infection in the prevention trial (gRNA)
[0260]
[0261] Note: “——” indicates that the mouse died due to factors other than antibodies or viruses, such as choking or overdose of anesthesia.
[0262] Table 8 Viral load in mouse lungs on day 3 after SARS-CoV-2 infection in the prevention trial (sgRNA)
[0263] Group 1 2 3 4 5 Processing Low-dose DIA-19 Medium-dose DIA-19 High-dose DIA-19 LY-cov1404 Unrelated antibodies Dosage (mg / kg) 1 5 20 20 20 Route of administration in in in in in Sample collection Day 3 after infection Day 3 after infection Day 3 after infection Day 3 after infection Day 3 after infection 1 7.56 7.83 6.29 9.35 8.66 2 6.88 6.29 6.21 8.95 8.56 3 5.99 6.02 6.21 8.33 8.85 4 6.73 6.19 ND 8.91 8.79 5 7.49 ND ND 9.73 9.03 6 6.31 —— —— 9.06 8.80 Mean 6.83 6.58 6.24 9.06 8.78 SD 0.57 0.73 0.04 0.43 0.15 Lower Mean 1.95 2.20 2.54 -0.28
[0264] Note: “——” indicates that the mouse died due to factors other than antibodies or viruses, such as choking or overdose of anesthesia; “ND” means not detected.
[0265] Table 9 Nasal viral load in mice on day 3 after SARS-CoV-2 infection in the prevention trial (sgRNA)
[0266]
[0267]
[0268]
[0269] Note: “——” indicates that the mouse died due to factors other than antibodies or viruses, such as choking or overdose of anesthesia; “ND” means not detected.
[0270] Example 9. Evaluation of the therapeutic effect of antibody DIA-19 injection on mice infected with the new coronavirus XBB strain
[0271] The purpose of this experiment is to evaluate the therapeutic effect of the candidate antibody DIA-19 on the SARS-CoV-2XBB strain in a mouse infection model. The experiment used 6-8 week old K18-hACE2 transgenic mice. After being infected with the SARS-CoV-2XBB strain, the candidate antibody DIA-19 was injected intraperitoneally (ip) to detect the virus clearance effect in the nasal cavity and lungs of the experimental mice. A total of 24 mice were set up in the intraperitoneal injection treatment experiment, divided into 4 groups, with 6 animals in each group, namely: 10mg / kg DIA-19 treatment group, 25mg / kg DIA-19 treatment group, 50mg / kg DIA-19 treatment group and PBS control group. Transgenic mice were infected with 1.5×10 4 Two hours after TCID50 of SARS-CoV-2XBB strain, different concentrations of DIA-19 antibody were injected intraperitoneally, and DIA-19 antibody was injected again 24 hours after the first treatment. The mice were euthanized on the fourth day after the challenge, and lung and nasal turbinate tissues were taken to detect the viral load (viral genome copy number) and pathological symptoms in the lungs and nasal cavity of the mice.
[0272] The experiment recorded the weight of mice on the day of infection with SARS-CoV-2XBB strain (Day 0) and for 4 consecutive days after infection. Fig. 7A shown.
[0273] Statistical analysis showed that at 4 days after viral infection, the lung viral gRNA and sgRNA loads were significantly reduced in the groups treated with 10 mg / kg, 25 mg / kg, and 50 mg / kg DIA-19 antibodies by intraperitoneal route compared with the PBS control group (e.g. Figure 7B The average loads of viral gRNA in the lungs were reduced by 1.57, 1.08 and 0.98 log10 copies / g, respectively (as shown in Table 10); the average loads of viral sgRNA in the lungs were reduced by 1.31, 0.88 and 0.77 log10 copies / g, respectively (as shown in Table 12).
[0274] Statistical analysis showed that on day 4 of viral infection, the intraperitoneal administration of 10 mg / kg, 25 mg / kg, and 50 mg / kg DIA-19 antibody groups significantly reduced the nasal viral gRNA and sgRNA loads compared with the PBS control group (e.g. Figure 7BThe average load of nasal virus gRNA decreased by 0.85, 1.10 and 1.25log10 copies / g, respectively (as shown in Table 11); the load of nasal virus sgRNA decreased by 0.90, 0.95 and 1.11log10 copies / g, respectively (as shown in Table 13).
[0275] The above results indicate that intraperitoneal injection of DIA-19 antibodies can effectively inhibit the replication of SARS-CoV-2XBB strain in the lungs and nasal cavity of transgenic mice and provide good protection for the mice.
[0276] Table 10 Virus load in mouse lungs on day 4 after SARS-CoV-2 infection in intraperitoneal injection treatment experiment (gRNA)
[0277]
[0278]
[0279] Table 11 Nasal viral load of mice on day 4 after SARS-CoV-2 infection in intraperitoneal injection treatment experiment (gRNA)
[0280] Group 1 2 3 4 Processing Low-dose DIA-19 Medium-dose DIA-19 High-dose DIA-19 PBS Dosage (mg / kg) 10 25 50 Route of administration ip ip ip ip Sample collection Day 4 after infection Day 4 after infection Day 4 after infection Day 4 after infection 1 8.93 8.74 8.16 9.93 2 8.47 7.87 8.40 9.25 3 8.87 8.92 8.56 9.54 4 8.68 8.74 8.48 9.76 5 9.03 8.66 8.10 9.73 6 9.04 8.64 8.92 9.92 Mean 8.84 8.59 8.44 9.69 SD 0.20 0.33 0.27 0.24 Lower Mean 0.85 1.10 1.25
[0281] Table 12 Viral load in mouse lungs on day 4 after SARS-CoV-2 infection in the intraperitoneal injection treatment experiment (sgRNA)
[0282] Group 1 2 3 4 Processing Low-dose DIA-19 Medium-dose DIA-19 High-dose DIA-19 PBS Dosage (mg / kg) 10 25 50 Route of administration ip ip ip ip Sample collection Day 4 after infection Day 4 after infection Day 4 after infection Day 4 after infection 1 6.87 7.01 8.09 8.67 2 7.94 6.81 6.84 8.32 3 7.44 8.28 8.19 8.79 4 8.18 8.94 7.76 8.49 5 4.73 7.40 8.10 8.27 6 8.35 7.65 7.79 8.80 Mean 7.25 7.68 7.79 8.56 SD 1.23 0.73 0.46 0.21 Lower Mean 1.31 0.88 0.77
[0283] Table 13 Nasal viral load of mice on day 4 after SARS-CoV-2 infection in intraperitoneal injection treatment experiment (sgRNA)
[0284] Group 1 2 3 4 Processing Low-dose DIA-19 Medium-dose DIA-19 High-dose DIA-19 PBS Dosage (mg / kg) 10 25 50 Route of administration ip ip ip ip Sample collection Day 4 after infection Day 4 after infection Day 4 after infection Day 4 after infection 1 6.89 6.79 6.51 8.03 2 6.67 6.45 6.72 7.42 3 7.05 6.99 6.73 7.64 4 6.60 6.86 6.75 7.83 5 7.08 7.09 6.28 7.75 6 7.00 6.81 7.02 8.00 Mean 6.88 6.83 6.67 7.78 SD 0.19 0.20 0.23 0.21 Lower Mean 0.90 0.95 1.11
[0285] Example 10. Study on the inhibitory effect of antibody DIA-19 on novel coronavirus Delta strain in mice
[0286] The purpose of this study is to determine the preventive and therapeutic protective effects of the candidate antibody DIA-19 against the SARS-CoV-2Delta strain in a mouse infection model. The study used 6-8 week old K18-hACE2 transgenic mice to evaluate the virus clearance effect of the candidate antibody DIA-19 in the brain and lungs of experimental mice after preventive and therapeutic administration.
[0287] A total of 30 mice were set up in the prevention test and divided into 5 groups, with 6 animals in each group, namely: 0.4mg / kg DIA-19 prevention group, 2mg / kg DIA-19 prevention group, 10mg / kg DIA-19 prevention group, 10mg / kg LY-cov1404 prevention group, and 10mg / kg irrelevant antibody control group. Six hours after the drug was intranasally administered, the transgenic mice were infected with 1×10 4 TCID50 of SARS-CoV-2Delta strain.
[0288] A total of 30 mice were set up in the treatment experiment and divided into 5 groups, with 6 animals in each group, namely: 5mg / kg DIA-19 treatment group, 10mg / kg DIA-19 treatment group, 30mg / kg DIA-19 treatment group, 30mg / kg LY-cov1404 treatment group, and 30mg / kg irrelevant antibody control group. Transgenic mice were infected with 1×10 4 TCID50 of SARS-CoV-2Delta strain was intraperitoneally injected 2 hours later. The viral load (viral gene copy number) and pathological symptoms in the brain and lungs of mice in both the prevention and treatment groups were tested on the third day after the challenge.
[0289] The results of the prevention trial showed that Figure 8 ), the groups that were given 0.4mg / kg DIA-19, 2mg / kg DIA-19, 10mg / kg DIA-19, and 10mg / kg control antibody LY-cov1404 by nasal drops for prevention had a statistically significant decrease in the average lung viral load of 4.05, 5.25, 5.51, and 6.31log10 copies / g, respectively, compared with the irrelevant antibody control group 3 days after virus infection. The groups that were given 2mg / kg DIA-19, 10mg / kg DIA-19, and 10mg / kg control antibody LYcov1404 by nasal drops for prevention had a statistically significant decrease in the average brain viral load of 3.96, 5.29, and 6.23log10 copies / g, respectively, compared with the irrelevant antibody control group 3 days after virus infection.
[0290] The results of treatment trials showed that ( Fig. 9), on day 3 of viral infection, the average lung viral loads in the 10mg / kg DIA-19 treatment group, the 30mg / kg DIA-19 treatment group, and the 30mg / kg control antibody LY-cov1404 treatment group were reduced by 0.78, 0.73, and 1.18log10 copies / g, respectively, compared with the irrelevant antibody control group, which was statistically significant. The average brain viral loads in the 5mg / kg DIA-19 treatment group, the 10mg / kg DIA-19 treatment group, the 30mg / kg DIA-19 treatment group, and the 30mg / kg control antibody LYcov1404 treatment group were reduced by 6.41, 6.18, 6.91, and 6.19log10 copies / g, respectively, compared with the irrelevant antibody control group, which was statistically significant.
[0291] The above results show that DIA-19 has good preventive and therapeutic protective effects against SARS-CoV-2Delta strain in the mouse infection model.
[0292] The antibody sequence information of the present invention is as follows:
[0293] SEQ ID NO.1 (DIA-19 sequence)
[0294] QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVAWIRQPPGKALEWLALIYWDNDKRSSPSLNNRLTITKDTSKNQVVLTMTNMDPEDTATYYCAHFFSHYDSSNYYYGSWFDPWGQGTLVTVSS GGGGSGGGGS DIQMTQSPSSSLSASVGDRVTITCRASQSISNYLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPFTFGPGTKVDIK GGGGSGGGGSGGGGSGGGGSGGGGS EVQLVESGGGVVQPGGSLRLSCAVSGFTFDDYAMHWVRQAPGKGLDWVSLISGDGSYTYYADSVKGRFTISRDSKNSLYLQMNSLRTEDTALYYCAKAQTPTLWWLQDAFDIWGQGTMVTVSS GGGGSGGGGS EIVLTQSPGTLSLSPGERATLSCRASQSFDSRYLGWYQQKSGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFGDSPFFTFGQGTKLEIK GGGGSDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK。
[0295] SEQ ID NO.2 (DIA-20 sequence)
[0296] EIVLTQSPGTLSLSPGERATLSCRASQSFDSRYLGWYQQKSGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFGDSPFTFGQGTKLEIKGGGGSGGGGSEVQLVESGGGVVQPGGSLRLSCAVSGFTFDDYAMHWVRQAPGKGLDWVSLISGDGSYTYYADSVKGRFTISRDSSKNSLYLQMNSLRTEDTALYYCAKAQTPTLWWLQDAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQSISNYLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPFTFGPGTKVDIKGGGGSGGGGSQITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVAWIRQPPGKALEWLALIYWDNDKRSSPSLNNRLTITKDTSKNQVVLTMTNMDPEDTATYYCAHFFSHYDSSNYYYGSWFDPWGQGTLVTVSSGGGGSDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK。
[0297] SEQ ID NO.3 (DIA-21 sequence)
[0298] EVQLVESGGGVVQPGGSLRLSCAVSGFTFDDYAMHWVRQAPGKGLDWVSLISGDGSYTYYADSVKGRFTISRDSSKNSLYLQMNSLRTEDTALYYCAKAQTPTLWWLQDAFDIWGQGTMVTVSSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLSCRASQSFDSRYLGWYQQKSGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFGDSPFTFGQGTKLEIKGGGGSGGGGSGGGGSGGGGSGGGGSQITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVAWIRQPPGKALEWLALIYWDNDKRSSPSLNNRLTITKDTSKNQVVLTMTNMDPEDTATYYCAHFFSHYDSSNYYYGSWFDPWGQGTLVTVSSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQSISNYLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPFTFGPGTKVDIKGGGGSDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK。
[0299] SEQ ID NO.4 (DIA-22 sequence)
[0300] DIQMTQSPSSLSASVGDRVTITCRASQSISNYLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPFTFGPGTKVDIKGGGGSGGGGSQITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVAWIRQPPGKALEWLALIYWDNDKRSSPSLNNRLTITKDTSKNQVVLTMTNMDPEDTATYYCAHFFSHYDSSNYYYGSWFDPWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLSCRASQSFDSRYLGWYQQKSGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFGDSPFTFGQGTKLEIKGGGGSGGGGSEVQLVESGGGVVQPGGSLRLSCAVSGFTFDDYAMHWVRQAPGKGLDWVSLISGDGSYTYYADSVKGRFTISRDSSKNSLYLQMNSLRTEDTALYYCAKAQTPTLWWLQDAFDIWGQGTMVTVSSGGGGSDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK。
[0301] SEQ ID NO.5 (Amino acid sequence of CoV56 light chain)
[0302] DIQMTQSPSSSLSASVGDRVTITCRASQSISNYLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSG TDFTLTISSLQPEDFATYYCQQSYSTPFTFGPGTKVDIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECS。
[0303] SEQ ID NO.6 (Amino acid sequence of CoV56 heavy chain)
[0304] EVQLVESGGGVVQPGGSLRLSCAVSGFTFDDYAMHWVRQAPGKGLDWVSLISGDGSYTYYADSVKGRF TISRDSSKNSLYLQMNSLRTEDTALYYCAKAQTPTLWWLQDAFDIWGQGTMVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK。
[0305] SEQ ID NO.7 (Amino acid sequence of L4.65 light chain)
[0306] EIVLTQSPGTLSLSPGERATLSCRASQSFDSRYLGWYQQKSGQAPRLLIYGASSRATGIPDRFSGSGS GTDFTLTISRLEPEDFAVYYCQQFGDSPTFFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECS。
[0307] SEQ ID NO.8 (Amino acid sequence of L4.65 heavy chain)
[0308] QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVAWIRQPPGKALEWLALIYWDNDKRSSPSLNNR LTITKDTSKNQVVLTMTNMDPEDTATYYCAHFFSHYDSSNYYYGSWFDPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK。
[0309] SEQ ID NO.9 (Amino acid sequence of the light chain of LY-CoV1404)
[0310] QSALTQPASVSGSPGQSITISCTATSSDVGDYNYVSWYQQHPGKAPKLMIFEVSDRPSGISNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTTSSAVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS。
[0311] SEQ ID NO.10 (Amino acid sequence of the heavy chain of LY-CoV1404)
[0312] QITLKESGPTLVKPTQTLTLTCTFSGFSLSISGVGVGWLRQPPGKALEWLALIYWDDDKRYSPSLKSRLTISKDTSKNQVVLKMTNIDPVDTATYYCAHHSISTIFDHWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK。
[0313] SEQ ID NO.11 (65 monoclonal antibody HCDR1) TSGVGVA。
[0314] SEQ ID NO.12 (65 monoclonal antibody HCDR2) LIYWDNDKRSSPSLNN。
[0315] SEQ ID NO.13 (65 monoclonal antibody HCDR3) FFSHYDSSNYYYGSWFDP。
[0316] SEQ ID NO.14 (65 monoclonal antibody LCDR1) RASQSFDSRYLG。
[0317] SEQ ID NO.15 (65 monoclonal antibody LCDR2) GASSRAT。
[0318] SEQ ID NO.16 (65 monoclonal antibody LCDR3) QQFGDSPFT。
[0319] SEQ ID NO.17 (56 monoclonal antibody HCDR1) DYAMH。
[0320] SEQ ID NO.18 (56 monoclonal antibody HCDR2) LISGDGSYTYYADSVKG。
[0321] SEQ ID NO.19 (56 monoclonal antibody HCDR3) AQTPTLWWLQDAFDI。
[0322] SEQ ID NO.20 (56 monoclonal antibody LCDR1) RASQSISNYLN。
[0323] SEQ ID NO.21 (56 monoclonal antibody LCDR2) VASSLQS。
[0324] SEQ ID NO.22 (56 monoclonal antibody LCDR3) QQSYSTPFT。
[0325] SEQ ID NO.23 (65 monoclonal antibody VH)
[0326] QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVAWIRQPPGKALEWLALIYWDNDKRSSPSLNNRLTITKDTSKNQVVLTMTNMDPEDTATYYCAHFFSHYDSSNYYYGSWFDPWGQGTLVTVSS。
[0327] SEQ ID NO.24 (65 monoclonal antibody VL)
[0328] EIVLTQSPGTLSLSPGERATLSCRASQSFDSRYLGWYQQKSGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFGDSPFTFGQGTKLEIK。
[0329] SEQ ID NO.25 (56 monoclonal antibody VH)
[0330] EVQLVESGGGVVQPGGSLRLSCAVSGFTFDDYAMHWVRQAPGKGLDWVSLISGDGSYTYYADSVKGRFTISRDSSKNSLYLQMNSLRTEDTALYYCAKAQTPTLWWLQDAFDIWGQGTMVTVSS。
[0331] SEQ ID NO.26 (56 monoclonal antibody VL)
[0332] DIQMTQSPSSLSASVGDRVTITCRASQSISNYLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPFTFGPGTKVDIK。
[0333] SEQ ID NO.27 (DIA-23 sequence)
[0334] QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVAWIRQPPGKALEWLALIYWDNDKRSSPSLNNRLTITKDTSKNQVVLTMTNMDPEDTATYYCAHFFSHYDSSNYYYGSWFDPWGQGTLVTVSSGGGG SGGGGSDIQMTQSPSSSLSASVGDRVTITCRASQSISNYLNWYQQKPGKAPKLLIYVASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPFTFGPGTKVDIKGGGGSGGGGSGGGGSGGGGS GGGGSEVQLVESGGGVVQPGGSLRLSCAVSGFTFDDYAMHWVRQAPGKGLDWVSLISGDGSYTYYADSVKGRFTISRDSKNSLYLQMNSLRTEDTALYYCAKAQTPTLWWLQDAFDIWGQGTMVTVSSGGG GSGGGGSEIVLTQSPGTLSLSPGERATLSCRASQSFDSRYLGWYQQKSGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFGDSPFTFGQGTKLEIKGGGGSDKTHTCPPCPAPE AA GGPSVFLFPPKPKDTL Y I T R E PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP PSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK.
[0335] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. A bispecific antibody against the new coronavirus, characterized in that: The bispecific antibody is formed by fusing the antigen-binding fragment of the first targeting domain D1 and the second targeting domain D2, and has two pairs of symmetrical peptide chains, each pair of peptide chains being connected by a disulfide bond, wherein: The first targeting domain D1 comprises a first heavy chain variable region VH1 and a first light chain variable region VL1, wherein, The first heavy chain variable region VH1 comprises: HCDR1, HCDR2 and HCDR3 whose amino acid sequences are shown in SEQ ID NO: 11, SEQ ID NO: 12 and SEQ ID NO: 13, respectively; The first light chain variable region VL1 comprises: LCDR1, LCDR2 and LCDR3 whose amino acid sequences are shown in SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 16, respectively; and The second targeting domain D2 comprises a second heavy chain variable region VH2 and a second light chain variable region VL2, wherein, The second heavy chain variable region VH2 comprises: HCDR1, HCDR2 and HCDR3 whose amino acid sequences are shown in SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO: 19, respectively; The second light chain variable region VL2 comprises: LCDR1, LCDR2 and LCDR3 whose amino acid sequences are shown as SEQ ID NO: 20, SEQ ID NO: 21 and SEQ ID NO: 22, respectively.
2. The bispecific antibody according to claim 1, wherein The amino acid sequence of the first heavy chain variable region is shown in SEQ ID NO: 23, and the amino acid sequence of the first light chain variable region is shown in SEQ ID NO: 24; and the amino acid sequence of the second heavy chain variable region is shown in SEQ ID NO: 25, and the amino acid sequence of the second light chain variable region is shown in SEQ ID NO:
26.
3. The bispecific antibody according to any one of claims 1 to 2, characterized in that The bispecific antibody is formed by fusion of the antigen-binding fragments of D1 and D2, and has two pairs of symmetrical peptide chains, each pair of peptide chains is connected by a disulfide bond, and any pair of peptide chains has a structure shown in formula ad from the N-terminus to the C-terminus: VH1-L1-VL2-L2-VH2-L3-VL1-L4-Fc Formula a VL1-L1-VH2-L2-VL2-L3-VH1-L4-Fc Formula b VH2-L1-VL1-L2-VH1-L3-VL2-L4-Fc Formula c VL2-L1-VH1-L2-VL1-L3-VH2-L4-Fc formula d; Wherein, L1, L2, L3, and L4 are each independently none, a bond, or a linker; Fc is the Fc element; "-" represents a peptide bond.
4. The bispecific antibody according to claim 3, characterized in that The Fc element has L234A and L235A mutations, or has L234A, L235A, M252Y, S254T and T256E mutations.
5. The bispecific antibody according to claim 4, characterized in that The bispecific antibody has an amino acid sequence selected from any one of SEQ ID NOs. 1-4 and 27.
6. A polynucleotide, characterized in that The polynucleotide encodes the bispecific antibody according to any one of claims 1 to 5.
7. A carrier, characterized in that The vector contains the polynucleotide according to claim 6.
8. A host cell, characterized in that The host cell contains the vector of claim 7 or the polynucleotide of claim 6 is integrated into its genome.
9. A method for preparing the bispecific antibody according to any one of claims 1 to 5, characterized in that: Includes steps: (i) culturing the host cell according to claim 8 to obtain a mixture containing the bispecific antibody according to any one of claims 1 to 5; (ii) purifying or separating the mixture obtained in step (i) to obtain the bispecific antibody according to any one of claims 1 to 5.
10. A pharmaceutical composition, characterized in that The pharmaceutical composition contains: (I) the bispecific antibody according to any one of claims 1 to 5; and (II) a pharmaceutically acceptable carrier.
11. The pharmaceutical composition according to claim 10, characterized in that The pharmaceutical composition is in the form of a nasal spray, an oral preparation, a suppository or a parenteral preparation.
12. Use of the bispecific antibody according to any one of claims 1 to 5 or the pharmaceutical composition according to claim 10 or 11, characterized in that: Used for preparing (a) detection reagents or kits; and / or (b) preparing drugs for preventing or treating novel coronavirus infection.
13. Use of the bispecific antibody according to any one of claims 1 to 5, the host cell according to claim 8, or the pharmaceutical composition according to claim 10 or 11, characterized in that: Used to prepare reagents or kits for preventing or detecting novel coronavirus infection; or used to prepare drugs for treating novel coronavirus infection.
14. The use according to claim 13, characterized in that The new coronavirus is the SARS-CoV-2 prototype strain or the SARS-CoV-2 variant strain.
15. The use according to claim 14, characterized in that The SARS-CoV-2 variant strain is selected from: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Kappa (B.1.617.1), Delta (B.1.617.2) variants or Omicron (B.1.1.529) and its sub-variants of SARS-CoV-2.
16. The use according to claim 14, characterized in that The new coronavirus is a SARS-CoV-2 selected from the following group: prototype strain, BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.3, BA.4, BA.5, BF.7, BQ.1, BQ.1.1, XBB, XBB.1.5, XBB.1.16, and EG.5 mutant strains.
